Progressive Pulmonary Fibrosis: focus on autoimmune ILDs
16/02/2023 | Author: Boehringer Ingelheim
Document ID: PC-SG-101833
EFFICACY
RELATED CONTENT
![SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-12/SG-607thumbnail.png)
SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD
![ofev-Consistent-efficacy-data-of-Ofev-in-all-severity-Infographic.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/ofev-Consistent-efficacy-data-of-Ofev-in-all-severity-Infographic.png)
Consistent treatment effect of OFEV® irrespective of disease stage at which it is initiated
![ofev-Efficacy-in-FVC-less-than-or-equal-to-50-population-Infographic-190123.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/ofev-Efficacy-in-FVC-less-than-or-equal-to-50-population-Infographic-190123.png)
OFEV® significantly reduces the risk of AE-IPF in the pooled INPULSIS®-1 and -2 and TOMORROW trials
![offv_slows_fvc_ decline_regardless_of_baseline_fvc_impairment_0.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/offv_slows_fvc_%20decline_regardless_of_baseline_fvc_impairment_0.png)
OFEV® slows FVC decline regardless of baseline FVC impairment
Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline
![exploratory_analysis_suggests_that_offv_may_extend_life_expectancy_and_is_well_tolerated_in_patients_with_ipf.png](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-08/exploratory_analysis_suggests_that_offv_may_extend_life_expectancy_and_is_well_tolerated_in_patients_with_ipf.png)